CD274 and neoplasm: Furthermore, the proportion of patients with numerically higher objective response rates and longer durations of response in the nivolumab plus chemotherapy cohort was larger than those in the chemotherapy alone cohort, among patients with the proportion of PD-L1-positive tumor cells to total tumor cells is greater than one percentage.